This commercial stage drug-device company that caters to patients with ear, nose, and throat conditions in the U.S. has seen no estimate revision in the last 60 days. However, the Zacks Consensus Estimate has moved higher over the same period. This implies solid trading potential for the company. So make sure to keep an eye on this stock going forward to see if yesterday’s climb can turn into more strength down the road.
Intersect ENT currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
A better-ranked Med-Instruments stock is Inogen, Inc. (INGN) with a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment